title: Update on glycoprotein IIb/IIIa: role in primary coronary intervention.
abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction. Platelets play a crucial role in thrombosis and haemostasis, which can be either beneficial or deleterious, depending on the circumstances. Platelet hyperreactivity is a multifactor process depending on genetic polymorphism, pathological state and lifestyle; it contributes to the activation of the thrombotic cascade. Under pathophysiological conditions platelets activation plays a critical role in arterial thrombosis including platelets aggregation, the basis of destabilization of coronary plaque. Despite the benefits observed in outcome when primary angioplasty is compared with thrombolysis for the treatment of acute myocardial infarction there is still some room for improvement; unfortunately the restoration of an "optimal" epicardial flow is not always related to an "optimal" myocardial reperfusion. In the recent, past several studies have shown significant benefits with the administration of glycoprotein IIb/IIIa inhibitors. Thus, the aim of the present review is to perform an update on factors associated with platelets hyperactivity and on adjunctive glycoprotein IIb - IIIa inhibitors in primary angioplasty.
authors.affiliation: Division of Cardiology, Ospedale Maggiore della Carità, Novara, Italy. arognoni@hotmail.com
authors.forename: Andrea
authors.initials: A
authors.lastname: Rognoni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lupi
authors.forename: Gioel Gabrio
authors.initials: GG
authors.lastname: Secco
authors.forename: Chiara
authors.initials: C
authors.lastname: Cavallino
authors.forename: Mara
authors.initials: M
authors.lastname: Sansa
authors.forename: Maurizio
authors.initials: M
authors.lastname: Lazzero
authors.forename: Angelo Sante
authors.initials: AS
authors.lastname: Bongo
mesh_terms: D000077284:Abciximab; D017130:Angioplasty / Q000379:methods*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab